Cargando…
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
In most protocols of peptide-based vaccination, no consideration has been paid to whether or not peptide-specific cytotoxic T-lymphocyte (CTL) precursors are pre-existent in cancer patients. Initiation of immune boosting through vaccination is better than that of immune priming to induce prompt and...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409683/ https://www.ncbi.nlm.nih.gov/pubmed/15054451 http://dx.doi.org/10.1038/sj.bjc.6601711 |
_version_ | 1782155832807391232 |
---|---|
author | Sato, Y Maeda, Y Shomura, H Sasatomi, T Takahashi, M Une, Y Kondo, M Shinohara, T Hida, N Katagiri, K Sato, K Sato, M Yamada, A Yamana, H Harada, M Itoh, K Todo, S |
author_facet | Sato, Y Maeda, Y Shomura, H Sasatomi, T Takahashi, M Une, Y Kondo, M Shinohara, T Hida, N Katagiri, K Sato, K Sato, M Yamada, A Yamana, H Harada, M Itoh, K Todo, S |
author_sort | Sato, Y |
collection | PubMed |
description | In most protocols of peptide-based vaccination, no consideration has been paid to whether or not peptide-specific cytotoxic T-lymphocyte (CTL) precursors are pre-existent in cancer patients. Initiation of immune boosting through vaccination is better than that of immune priming to induce prompt and strong immunity. In this study, 10 human histocompatibility leukocyte antigen-A24(+) patients with advanced colorectal carcinomas were treated with up to four peptides that had been positive for pre-vaccination measurement of peptide-specific CTL precursors in the circulation (CTL precursor-oriented peptide vaccine). No severe adverse effect was observed, although local pain and fever of grade I or II were observed. Post-vaccination peripheral blood mononuclear cells (PBMCs) from five patients demonstrated an increased peptide-specific immune response to the peptides. Increased CTL response to cancer cells was detected in post-vaccination PBMCs of five patients. Antipeptide immunoglobulin G became detectable in post-vaccination sera of seven patients. Three patients developed a positive delayed-type hypersensitivity response to at least one of the peptides administrated. One patient was found to have a partial response; another had a stable disease, sustained through 6 months. These results encourage further development of CTL precursor-oriented vaccine for colorectal cancer patients. |
format | Text |
id | pubmed-2409683 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-24096832009-09-10 A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients Sato, Y Maeda, Y Shomura, H Sasatomi, T Takahashi, M Une, Y Kondo, M Shinohara, T Hida, N Katagiri, K Sato, K Sato, M Yamada, A Yamana, H Harada, M Itoh, K Todo, S Br J Cancer Clinical In most protocols of peptide-based vaccination, no consideration has been paid to whether or not peptide-specific cytotoxic T-lymphocyte (CTL) precursors are pre-existent in cancer patients. Initiation of immune boosting through vaccination is better than that of immune priming to induce prompt and strong immunity. In this study, 10 human histocompatibility leukocyte antigen-A24(+) patients with advanced colorectal carcinomas were treated with up to four peptides that had been positive for pre-vaccination measurement of peptide-specific CTL precursors in the circulation (CTL precursor-oriented peptide vaccine). No severe adverse effect was observed, although local pain and fever of grade I or II were observed. Post-vaccination peripheral blood mononuclear cells (PBMCs) from five patients demonstrated an increased peptide-specific immune response to the peptides. Increased CTL response to cancer cells was detected in post-vaccination PBMCs of five patients. Antipeptide immunoglobulin G became detectable in post-vaccination sera of seven patients. Three patients developed a positive delayed-type hypersensitivity response to at least one of the peptides administrated. One patient was found to have a partial response; another had a stable disease, sustained through 6 months. These results encourage further development of CTL precursor-oriented vaccine for colorectal cancer patients. Nature Publishing Group 2004-04-05 2004-03-02 /pmc/articles/PMC2409683/ /pubmed/15054451 http://dx.doi.org/10.1038/sj.bjc.6601711 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Sato, Y Maeda, Y Shomura, H Sasatomi, T Takahashi, M Une, Y Kondo, M Shinohara, T Hida, N Katagiri, K Sato, K Sato, M Yamada, A Yamana, H Harada, M Itoh, K Todo, S A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients |
title | A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients |
title_full | A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients |
title_fullStr | A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients |
title_full_unstemmed | A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients |
title_short | A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients |
title_sort | phase i trial of cytotoxic t-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409683/ https://www.ncbi.nlm.nih.gov/pubmed/15054451 http://dx.doi.org/10.1038/sj.bjc.6601711 |
work_keys_str_mv | AT satoy aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT maeday aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT shomurah aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT sasatomit aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT takahashim aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT uney aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT kondom aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT shinoharat aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT hidan aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT katagirik aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT satok aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT satom aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT yamadaa aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT yamanah aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT haradam aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT itohk aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT todos aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT satoy phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT maeday phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT shomurah phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT sasatomit phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT takahashim phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT uney phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT kondom phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT shinoharat phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT hidan phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT katagirik phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT satok phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT satom phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT yamadaa phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT yamanah phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT haradam phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT itohk phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients AT todos phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients |